ORIC Pharmaceuticals, Inc.

CG Oncology, Inc. achieved what no biopharmaceutical company has been able to do for more than two months – it went public in the US. The bladder cancer drug developer also launched the first initial

The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Hopes Owkin Can Aid Oncology Dis

While COVID-19-related deals have largely dominated the global biopharma industry this year, the alliances reached by South Korean companies in the sector in 2020 ranged widely, from oncology to non-a